Advarra has announced new technology functionality to its solution, Longboat, an established platform used in more than 70 countries and by nearly 20,000 sites. It now features an online patient portal with a set of engagement tools including a document exchange that enables transparent collaboration between patients, sites, and sponsors or clinical research organizations (CROs) without adding technology burden.
Because the patient portal module is part of the same platform the site uses for essential document collection, training/learning management, study conduct enablement tools, and safety letter viewing and acknowledgement, sites are able to provide a more connected experience for their patients with this workflow.
"We've been listening to sites who are drowning in administrative tasks, repeatedly entering the same information, having to log into multiple systems or feeling out of the loop with direct communication between the sponsor and patient," said Elisa Cascade, chief product officer at Advarra in a press release. "A connected system with site, sponsor, CRO, and patient access provides visibility to all while preserving the site-patient relationship. This transparent collaboration in real time is a win for everyone involved in the study."
Advarra Launches Next-Generation Technology to Align Patients, Sites, and Sponsors in Clinical Trials. (2023, October 4). Cision PR Newswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.